Amneal obtains non-infringement finding in Sensipar case
01-08-2018
tumsasedgars / iStockphoto.com
Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar (cinacalcet hydrochloride).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Heritage Pharmaceuticals, Emcure Pharmaceuticals, generics, ANDA, FDA, patent infringement, Sensipar
